Clinical Trial

Creatine Supplementation and Resistance Training to Preserve Muscle Mass and Attenuate Cancer Progression

Study acronym: CREATINE-52
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to test the use of creatine monohydrate supplementation with resistance training to preserve muscle mass and help lessen prostate cancer progression. The main question it aims to answer is if this treatment will help maintain muscle mass to help in reducing fatigue and improving physical function, independence, and quality of life. Participants will be asked to participate in a 52-week exercise intervention consisting of a twice weekly telehealth resistance training program.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-10-30; most recent amendment 2026-06-01.
Status change: Not Yet Recruiting → Recruiting 2023-12-20
Trial Details
NCT Number NCT06112990
Lead Sponsor University of Utah
Collaborators: National Cancer Institute (NCI)
Conditions Metastatic Prostate Cancer
Enrollment 200 participants
Start Date 2023-11-09
Primary Completion 2028-11-30 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-03